Scarica l'app Stockscreener
4.48
1.13%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BLRX Giù?
Forum
Previsione
Frazionamento azionario
Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie
Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India
BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks
Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa
Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks
BioLineRx reports promising pancreatic cancer trial data - Investing.com
JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks
BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks
BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
Options Volatility and Implied Earnings Moves Today, March 31, 2025 - TipRanks
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BLRX: Aphexda Transition Progressing - Research Tree
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks
BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India
BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com
0.15%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):